Drug profile

The FDA adverse-event record for Subcutaneous Fluid Therapy

34 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Subcutaneous Fluid Therapy. Species, reactions, and outcomes follow.

#1363 of 2,679
by report volume (all drugs)
34
adverse-event reports
20.6%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Subcutaneous Fluid Therapy ranks #1344 of 2679 by total reports (34). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1344
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Subcutaneous Fluid Therapy has 34 reports now versus 34 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Subcutaneous Fluid Therapy changes

Signature read: Subcutaneous Fluid Therapy's 20.6% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
7
Deaths Reported
20.6%
Death-coded share of reports

Active Ingredients

Subcutaneous Fluid Therapy

Administration Routes

SubcutaneousOralUnknown

Species Affected

Dog 20
Cat 14

Most Affected Breeds

Domestic Shorthair 10
Chihuahua 4
Retriever - Labrador 2
Bengal 2
Shih Tzu 2
Terrier - Yorkshire 1
Domestic Longhair 1
Siamese 1
Poodle (unspecified) 1
Beagle 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 11
Not eating 6
Elevated alanine aminotransferase (ALT) 5
Weight loss 5
Death by euthanasia 4
Neutrophilia 4
Vomiting 4
Tremor 4
Not himself/herself 4
Low platelet count 4
Diarrhoea 3
Pain NOS 3

Outcome Breakdown

Ongoing
22 (64.7%)
Euthanized
4 (11.8%)
Recovered/Normal
4 (11.8%)
Died
3 (8.8%)
Outcome Unknown
1 (2.9%)

Subcutaneous Fluid Therapy: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Subcutaneous Fluid Therapy (#1363 of 2,679 by report volume); death-coded 20.6%. PlainBreed drug row · death-coded share stamp 20.6% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →